Pharyngitis Treatment Global Market Report 2024

The global pharyngitis treatment market has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.27 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence and growing incidence of flu, rising prevalence of pharyngitis, growing awareness of pharyngitis, increasing access to healthcare, rising disposable incomes.

The global pharyngitis treatment market is expected to see strong growth in the next few years. It will grow to $2.8 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to adoption of rapid point-of-care tests, demand for personalized medicine, prevalence of antibiotic resistance, rising importance of hand hygiene. Major trends in the forecast period include advancements in research and development of pharyngitis therapies, digital health technologies, telehealth integration,.

The increasing transmission of strep throat is poised to drive the expansion of the pharyngitis treatment market. Strep throat is a contagious bacterial infection primarily affecting the throat and tonsils. Swift and effective treatment of strep throat with antibiotics is crucial for symptom relief, complication prevention, and reducing the risk of spreading the infection to others. For example, as of June 2022, data from the Centers for Disease Control and Prevention, a US-based government agency, reveals an annual occurrence of approximately 14,000 to 25,000 cases of invasive group A strep disease in the United States. Furthermore, strep-related diseases prompt 5.2 million outpatient visits and result in 2.8 million antibiotic prescriptions each year. Thus, the increased transmission of strep throat is a significant driver of growth in the pharyngitis treatment market.

The increasing prevalence of influenza is anticipated to drive the expansion of the pharyngitis treatment market. Influenza, commonly referred to as the flu, is a contagious respiratory illness caused by influenza viruses. Pharyngitis treatment plays a pivotal role in addressing influenza, offering relief from symptoms, including inflammation and irritation of the throat, and focusing on managing allergies while preventing complications like pneumonia and bronchitis. For example, data published by the Centers for Disease Control and Prevention (CDC), a US-based government agency, in May 2023, revealed 9 million cases of flu (influenza) in the United States between 2021 and 2022, resulting in 5,000 recorded deaths. Consequently, the increasing incidence of influenza is a key driver of growth in the pharyngitis treatment market.

The influence of patient non-compliance is impeding the progress of the pharyngitis treatment market during the projected period. Failure by patients to adhere to prescribed treatment protocols can lead to delays in their recovery from pharyngitis, resulting in prolonged illness. This extended period of discomfort and hardship might leave patients unsatisfied with the treatment, potentially generating negative word-of-mouth feedback. For example, as of 2022, research published by the BMJ Publishing Group Ltd., a UK-based publisher, indicates that approximately 30% to 50% of individuals with chronic conditions are believed not to adhere to their prescribed medication regimens. Consequently, the effect of patient non-compliance poses a hindrance to the growth of the pharyngitis treatment market.

The prominent companies in the pharyngitis treatment market are introducing innovative products as part of their strategy to maintain their market position. For example, in a notable development, RB Health (US) LLC, a pharmaceutical company based in the United States, unveiled the Mucinex InstaSoothe product line in November 2021. This product line comprises lozenges and sprays engineered to provide relief from sore throat discomfort, also referred to as pharyngitis. The range includes clinically validated sore throat and soothing comfort lozenges, sore throat and cough relief lozenges, and Mucinex InstaSoothe sore throat and pain relief spray. These lozenges are crafted with natural honey and contain 2.4 mg of hexylresorcinol, delivering rapid relief for up to 2 hours. The spray features benzocaine and menthol, offering temporary pain relief and throat soothing properties.

In July 2021, Verfora, a pharmaceutical company headquartered in Switzerland, successfully completed the acquisition of Spagyros Ltd., with the transaction's financial details remaining undisclosed. This strategic move by Verfora is aimed at bolstering its pharmacy and drugstore offerings with a range of products that necessitate in-depth consultations, ultimately reinforcing the company's position in the Swiss consumer healthcare market. Spagyros Ltd., a Switzerland-based enterprise, specializes in the production of phytotherapy and complementary medicines, including treatments for sore throat ailments.

Major players in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

North America was the largest region in the pharyngitis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharyngitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary classes of drugs used in pharyngitis treatment encompass beta-lactams, macrolides, cephalosporins, fluoroquinolones, tetracyclines, and other categories. Beta-lactams are a class of antibiotics distinguished by the presence of a beta-lactam ring in their chemical structure. Infections can stem from various sources, including viral and bacterial agents. Additionally, treatments are administered through various modes, such as oral, intravenous, intramuscular, and others, catering to diverse end-users, including hospitals, homecare settings, specialty centers, and more.

This report provides pharyngitis treatment market statistics, including pharyngitis treatment industry global market size, regional shares, competitors with a pharyngitis treatment market share, detailed pharyngitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the pharyngitis treatment industry. This pharyngitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharyngitis treatment market consists of sales of antibiotics, antiviral drugs and antifungal medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.